Monday, April 20, 2026 – By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.
Monday, April 20, 2026 – Here’s everything we know so far.
Monday, April 20, 2026 – (MedPage Today) -- GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.
Using U.S. electronic health record data, the incidence of...
Monday, April 20, 2026 – A newly discovered molecule could reshape the future of weight loss treatments by mimicking the powerful appetite-suppressing effects of drugs like Ozempic — but without many of the unpleasant side effects. Identified using artificial intelligence, this tiny peptide, called BRP, appears to act directly on the brain’s appetite-control center, helping animals eat less and lose fat without nausea or muscle loss.
Monday, April 20, 2026 – Researchers at Toronto's Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1—acts directly on a subset of liver cells to improve organ function and does so independently of weight loss. The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease.
Monday, April 20, 2026 – (MedPage Today) -- Eating the same meals every day may aid in weight loss, according to a study of real-time food tracking data. (Health Psychology)
The prevalence of youth-onset type 2 diabetes increased substantially from 2013 to 2024, rising...
Monday, April 20, 2026 – If you watched the Super Bowl in 2026, you likely saw Serena Williams share her weight loss journey on GLP-1 medications in a commercial.
Monday, April 20, 2026 – Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.
Monday, April 20, 2026 – INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in...
Monday, April 20, 2026 – THURSDAY, April 16, 2026 -- Social media posts about glucagon-like peptide-1 receptor agonists may identify patient concerns not captured in clinical trials, according to a study published online April 10 in Nature Health.
Neil K.R. Sehgal, from...